AML Education
AML treatment requires rapid molecular characterization and risk-adapted therapy selection. Knowledge Med sessions help community providers work through complex AML cases using interactive simulations — from initial workup to consolidation and maintenance decisions.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing acute myeloid leukemia face evolving treatment decisions that interactive, independently reviewed education can help address.
- Interpreting molecular markers (FLT3, IDH1/2, NPM1, TP53) to guide therapy
- Selecting between intensive and lower-intensity regimens based on fitness
- Integrating targeted agents (FLT3 inhibitors, IDH inhibitors) into treatment
- Managing venetoclax-based regimens in older or unfit patients
What Sessions Cover
Knowledge Med AML sessions use interactive case simulations to address these topics and more.
- Molecular-guided frontline therapy selection in AML
- Venetoclax-azacitidine: optimization and monitoring
- FLT3-mutated AML: midostaurin, gilteritinib, and emerging agents
- IDH-mutated AML: targeted therapy integration and combinations
Interactive AML Sessions
Case Simulations
Work through realistic acute myeloid leukemia patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key AML clinical takeaways.
More Hematologic Malignancy Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Chronic Lymphocytic Leukemia
CLL / SLL — First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
Diffuse Large B-Cell Lymphoma
DLBCL — Frontline DLBCL: pola-R-CHP and risk-adapted strategies
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Myelodysplastic Syndromes
MDS — IPSS-M and molecular risk stratification in MDS
Join a AML Session
Third-party, non-promotional acute myeloid leukemia education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session